Johnson & Johnson
Recent News About Johnson & Johnson
-
Big Risperdal trial in Philadelphia turns to statistical reanalysis; J&J facing punitive damages in gynecomastia cases
PHILADELPHIA – Testimony in the punitive damages trial for Risperdal on Thursday turned to both a statistical reanalysis of original clinical trial data as well as a 2003 article on the drug, which plaintiff counsel quoted one of its own original authors referring to as both “despicable” and “the poster boy of bad behavior.” -
'Kline Science': J&J official disputes plaintiffs lawyers' take on Risperdal trial data
PHILADELPHIA – In continuing testimony taken during the first punitive damages trial surrounding anti-psychotic drug Risperdal in Philadelphia, a doctor who worked for Johnson & Johnson and its subsidiary Janssen Pharmaceuticals testified that the elevated prolactin levels of some boys participating in the drug’s early clinical trials were relevant, but not concerning at that time. -
Jurors won't get confused during huge opioid trial, judge rules; He'll set penalties after
CLEVELAND (Legal Newsline) – A jury will determine who, if anyone, is liable for the nation’s addiction crisis, but the judge overseeing a historic trial will decide how much they would pay. -
At first-of-its-kind trial in Philadelphia, J&J says there were no 'spin' tactics with Risperdal
PHILADELPHIA – In continuing testimony taken during the first punitive damages trial surrounding anti-psychotic drug Risperdal in Philadelphia, a Johnson & Johnson senior director said that the company and its subsidiary Janssen Pharmaceuticals were not responsible for attempting to “spin” information provided to the media about the medication. -
J&J senior director says Risperdal targeting to child doctors wasn't off-label promotion
PHILADELPHIA – Johnson & Johnson did not market anti-psychotic drug Risperdal off-label to pediatricians and pediatric psychologists prior to receiving Food & Drug Administration approval, according to a senior official testifying in a trial meant to determine if the pharmaceutical giant will be penalized with punitive damages. -
Ex-FDA commissioner says Risperdal was promoted for kids before it was approved; J&J maintains it was safe
PHILADELPHIA – Testimony in the Risperdal punitive damages trial continued Thursday with a former Food & Drug Administration commissioner who said Johnson & Johnson and its subsidiary Janssen Pharmaceuticals sought to promote use of Risperdal in children and adolescents, before it was given such approval – but the company maintains it was safe for that age group. -
Philly judge shoots down J&J's mistrial motion on first day of Risperdal punitive damages trial
PHILADELPHIA – On the first day of a trial that could expose Johnson & Johnson to millions of dollars in punitive damages, the company moved for a mistrial after plaintiffs attorneys reminded jurors of its massive value but was denied. -
J&J wants to use plaintiff's own doctors to fight against punitive damages in Risperdal case
PHILADELPHIA – In pre-trial bench memorandums filed over the weekend, Johnson & Johnson believes the testimony of prescribing physicians would provide additional context for its actions in trying to repel a punitive damages claim made against it by a man who alleges he was disfigured by Risperdal’s side effect of gynecomastia. -
Trial to determine jackpot-potential of Risperdal lawsuits starts today in Philadelphia
PHILADELPHIA – On Monday, a new punitive damages trial will begin in a Philadelphia courtroom for a case involving anti-psychotic drug Risperdal that initially ended with a $1 million-plus plaintiff verdict in 2015, in a jurisdiction with a history of high-dollar results. -
Philadelphia judge denies J&J's attempt to avoid upcoming Risperdal punitive damages trial
PHILADELPHIA – A state court judge decided that a new punitive damages trial will proceed in a Risperdal action that initially resulted in a $1 million-plus verdict in 2015 – above Johnson & Johnson’s attempt to dismiss the case through a motion for summary judgment. -
Philly judge recommends Superior Court affirm $41M pelvic mesh verdict against Johnson & Johnson subsidiary
PHILADELPHIA – A Philadelphia judge who presided over a case where a Lancaster woman claimed she suffered permanent injuries to her genitalia after the installation of a pelvic mesh implant manufactured by Johnson & Johnson subsidiary Ethicon, Inc., is recommending the Superior Court of Pennsylvania affirm the action’s $41 million verdict on appeal. -
Oklahoma judge feeds the 'monster' with $572M opioid ruling against Johnson & Johnson
Sixteen years ago in a case involving gunmaker Sturm, Ruger & Co., a New York appeals court refused to apply public nuisance law against the manufacturer of a legal product, saying that doing so would transform nuisance law “into a monster that would devour in one gulp the entire law of tort.” -
Private lawyers stand to make $90 million as judge hits Johnson & Johnson with $572M opioid ruling
NORMAN, Okla. (Legal Newsline) - A state judge in Oklahoma has blamed Johnson & Johnson for the state's opioid crisis and ordered it to pay $572 million in damages, extending public nuisance law beyond its traditional boundaries into what may become an all-purpose tool for government lawsuits against product manufacturers. -
Pa. Supreme Court declines to hear Janssen's appeal in $2.5 million Risperdal case
HARRISBURG – According to the Supreme Court of Pennsylvania, it will not hear an appeal of the first Risperdal case to be decided in the hands of a Philadelphia jury and its $2.5 million verdict for the plaintiff will stand. -
Eight-day hearing on viability of witnesses in talc lawsuits set to conclude
TRENTON, N.J. – Eight days of scientific expert witness testimony in a New Jersey federal court, centered on whether Johnson & Johnson’s talc-containing baby powder causes women to develop both ovarian cancer and mesothelioma, will conclude Wednesday and ultimately determine if 12,000 lawsuits on the subject move forward. -
Facing 12,000 lawsuits, J&J has expert testify that there is no link between talc and ovarian cancer
TRENTON, N.J. – The fate of about 12,000 lawsuits claiming Johnson & Johnson’s talc-containing baby powder causes women to develop both ovarian cancer and mesothelioma, will be decided after eight days of expert witness testimony in a New Jersey federal court. -
Janssen win in Philly Risperdal case overturned by appeals court
HARRISBURG – The Superior Court of Pennsylvania has reinstated a Risperdal lawsuit which was thrown out after 11 days of trial proceedings in a Philadelphia court in December 2016 and said its original granting of nonsuit was improper. -
Tensions run high in OK opioid trial Thursday; State focuses on risk data J&J relied on
NORMAN, Okla. (Legal Newsline) - Tensions ran high in court Thursday as the Oklahoma opioid trial continued, with defense attorney Larry Ottoway objecting throughout the day to opposing counsel's line of questioning directed at defense witness, business director for Janssen Pharmaceuticals Kimberly Deem-Eshleman. -
Father recounts loss of son in Oklahoma Johnson & Johnson opioid trial
NORMAN, Okla. (Legal Newsline) – Fighting back tears, a father who lost his son to an opioid overdose recounted the nightmare during testimony in a trial alleging that Johnson & Johnson flooded the state with addictive drugs for profit. -
Hunter: Case is about abating 'worst' man-made crisis; J&J: Case is about damages - not abatement
NORMAN, Okla. (Legal Newsline) - Admitting there is a high potential for abuse in opioid medications, Johnson & Johnson attorney Larry Ottaway said during opening arguments on Tuesday that physicians prescribing its medications Nucynta and Duragesic know this risk and have to know it to be licensed.